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Background. We have previously demonstrated an essential
role for increased epidermal growth factor receptor (EGFR)
activity in mediating renal cyst formation and biliary ductal
ectasia (BDE) in murine models of autosomal-recessive poly-
cystic kidney disease (ARPKD) such as the BPK mouse. The
current study was designed to determine (1) if treatment with
a second-generation inhibitor of EGFR tyrosine kinase activity,
EKB-569, was effective in treatment of ARPKD; (2) if tyrosine
kinase inhibitor therapy used in combination with pharmaco-
logic reduction of the availability of transforming growth fac-
tor- (TGF-), using WTACE2, could provide improved thera-
peutic efficacy and/or decrease potential toxicity; and (3) if
effectiveness of treatment could be monitored noninvasively
in murine ARPKD models by use of serial ultrasonography.
Methods. BPK litters were treated with EKB-569 by intra-
peritoneal injection from postnatal day 7 to postnatal day 21.
EKB-569’s effectiveness alone or in combination with WTACE2
was measured by reduction in kidney weight/body weight ra-
tios, morphometric renal cystic index, and evaluation of renal
function. Renal ultrasound was performed on normal and cystic
animals, under different therapeutic regimens, utilizing a 15
mHz linear array transducer, and ultrasound data were com-
pared with histology and renal functional data.
Results. Treatment of BPK mice with EKB-569 alone re-
sulted in a marked reduction of kidney weight/body weight
ratios, dramatically reduced collecting tubule cystic index, as
well as BDE, and improved renal function. The combined
treatment with EKB-569 and WTACE2 permitted a 67% re-
duction in EKB-569 dosage necessary to achieve results equiva-
lent to those produced with EKB-569 alone. Untreated cystic
animals died of renal failure, on average, at postnatal day 24
with a collecting tubule cystic index of 4.8, significant BDE,
and maximal urine osmolarity of 361 mOsm. Cystic animals
treated with EKB-569 and WTACE2 to postnatal day 21 were
alive and well with normal renal function, a reduced collecting
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tubule cystic index of 1.7 (P  0.02), improvement in BDE,
and a threefold increase in maximum urinary concentrating
ability (P 0.01). Renal ultrasound could reliably detect cystic
kidneys as early as postnatal day 7 and the natural history as
well as effects of therapeutic intervention were clearly deline-
ated by ultrasound evaluation.
Conclusion. This study demonstrates that in murine ARPKD
(1) EKB-569 is as effective as first-generation EGFR tyrosine
kinase inhibitors in reducing cyst formation and preserving
renal function; (2) combination therapy with EKB-569 and
WTACE2 provides maximum efficacy in improving renal and
biliary abnormalities, at lower doses, thereby minimizing po-
tential toxicity; and (3) renal ultrasound provides a simple,
reliable, noninvasive method of following natural history and
effect of treatment regimens.
Polycystic kidney disease (PKD), a leading cause of
end-stage renal disease, encompasses two genetically dis-
tinct conditions: autosomal-dominant polycystic kidney
disease (ADPKD) and autosomal-recessive polycystic
kidney disease (ARPKD) [1]. ADPKD occurs in 1:300
to 1:1000 individuals and most, if not all, disease is caused
by mutations in one of two known genes, PKD1 or PKD2
[2, 3]. ADPKD is characterized by renal cyst formation
in all tubular segments and extrarenal manifestations,
including hepatic and pancreatic cysts, cerebral aneu-
rysms, and an increased incidence of diverticulosis and
valvular heart abnormalities [4]. ARPKD occurs less
frequently, in approximately 1:20,000 live births, and all
clinical cases appear to result from mutations in a single,
recently identified gene, PKHD1 [5, 6]. ARPKD is in-
variably characterized by the formation and enlargement
of renal collecting tubule cysts as well as biliary ductal
plate abnormalities [biliary ductal ectasia (BDE)] and
hepatic fibrosis [7].
Cystic renal epithelia share common phenotypic ab-
normalities despite the different genetic mutations that
underlie the disease. Numerous animal models as well
as in vitro cell culture systems utilizing human and animal
kidney cells have been used to delineate the cellular
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pathophysiology of cystogenesis. These studies have re-
ported abnormalities in fluid secretion, extracellular ma-
trix composition, differentiation, and focal epithelial
cellular proliferation [8]. Evidence from a number of
laboratories demonstrates a significant role for the epi-
dermal growth factor receptor (EGFR) axis in promoting
epithelial hyperplasia in cystic epithelia, with resultant
renal cyst formation and enlargement in both murine
and human ADPKD and ARPKD [9–19]. In addition,
evidence from murine models suggests that similar ab-
normalities of the EGFR axis may mediate biliary epi-
thelial hyperplasia and BDE [13, 14, 20].
We have previously identified a central role for in-
creased EGFR tyrosine kinase activity in promoting re-
nal cyst formation and progressive enlargement by dem-
onstrating a direct correlation between reduced cyst
formation and decreased EGFR activity (i.e., autophos-
phorylation). Reduction of EGFR activity was accom-
plished, in vivo, by (1) genetic manipulation [18]; (2)
pharmacologic inhibition of receptor activation with
EKI-785 (EKI), an agent that covalently binds to the
EGFR adenosine triphosphate (ATP) binding site [20, 21];
and (3) pharmacologic reduction of the availability of a
cystogenic EGFR ligand, transforming growth factor-
alpha (TGF-) with a tumor necrosis factor- (TNF-)
converting enzyme inhibitor, WTACE2 [22]. The pur-
pose of the current study was to determine if a second-
generation inhibitor of EGFR tyrosine kinase activity,
EKB-569 (EKB) [23], was (1) as effective as EKI in
reducing the development and enlargement of collecting
tubule cysts and BDE in a well-characterized murine
model of ARPKD; and (2) could be used in combination
with WTACE2 to improve therapeutic response or per-
mit reduction in doses of EKB while maintaining effec-
tive tyrosine kinase activity reduction. In addition, the
feasibility of using renal ultrasound to identify cystic
kidneys at an early stage of renal cyst formation and to
utilize sonography as a noninvasive method to monitor
the natural history of disease as well as therapeutic effec-
tiveness of specific therapies was evaluated.
Results demonstrate that EKB was as effective as EKI
in retarding in vivo renal cyst formation and BDE in
BPK cystic mice, resulting in a marked reduction in the
number and size of collecting tubule cystic lesions and
improved renal survival and tubular function. Pharmaco-
logic inhibition of EGFR activity with EKB used in com-
bination with WTACE2 permitted a 67% reduction in
EKB dosage necessary to maximally effect collecting tu-
bule cyst reduction, preserve renal function, and minimize
BDE. In addition, renal ultrasound provided a reliable,
noninvasive, means of monitoring the natural history
and effectiveness of experimental therapeutic regimens
in vivo.
METHODS
EGFR tyrosine kinase inhibition
Tyrosine kinase inhibition was accomplished with
EKB, a derivative of EKI, with improved pharmacoki-
netics and enteral bioavailability compared to the parent
compound, EKI [23]. EKB covalently binds to EGFR,
inhibits kinase activity of the protein (IC50  38.5 nmol/L),
blocks EGF-stimulated autophosphorylation of the re-
ceptor without changing the total amount of EGFR pro-
tein, inhibits cell proliferation, and blocks the growth of
tumors that overexpress EGFR [23]. The duration of
EKB activity is dependent upon the half-life of the com-
pound as well as the turnover rate of EKB-bound EGFR
in the plasma membrane. Preliminary time course and
dose response experiments demonstrated that intraperi-
toneal administration of EKB every 3 days resulted in
optimal receptor inhibition with minimal toxicity.
Reduction of ligand availability
TGF- is produced as a prepropeptide that undergoes
proteolytic cleavage at the cell membrane to produce
the mature, secreted moiety [24]. The cleavage of the
prepropeptide is mediated by TNF- converting enzyme
(also known as Adam 17) [25]. Reduction of soluble
TGF-was accomplished with WTACE2, a novel metal-
loproteinase inhibitor specific for TNF- converting en-
zyme developed by Wyeth-Ayerst Research (Pearl River,
NJ, USA). WTACE2 is an orally active, broad-spectrum
inhibitor of matrix metalloproteinase (MMP) with nano-
molar activity against MMP-1, MMP-9, and MMP-13 and
little or no toxicity demonstrated at doses of 250 mg/kg
per day [22].
The Balb/c-bpk/bpk (BPK) model
The BPK model, a murine model of ARPKD, arose
as a spontaneous mutation in an inbred colony of Balb/c
mice and has been extensively characterized [19]. Homo-
zygous BPK mice, bpk/bpk, mimic human ARPKD, in-
cluding the development of large collecting tubule cysts,
and BDE. Affected animals develop massively enlarged
kidneys and die of renal failure at an average postnatal
age of 24 days [13, 14, 20]. Due to the recessive nature
of this disease, wild-type/ and heterozygous bpk/
mice are phenotypically normal.
Dose response studies
Entire litters from proven BPK heterozygous breeders
(including BPK cystic bpk/bpk, heterozygous bpk/, and
wild-type/ pups) received EKB at 30, 60, or 90 mg/kg,
by intraperitoneal injections every 3 days starting at post-
natal day 7. These dosages were based on previous phar-
macologic studies of EKI in the BPK mouse [26] and
published pharmacokinetic data comparing EKI and
EKB effectiveness [23]. Morphologic analysis was per-
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formed to determine reduction of renal cystic lesions as
well as biliary proliferation and BDE and evaluation of
renal and extrarenal organ toxicity. Animals were
treated from postnatal day 7 to postnatal day 19 (five
doses), and kidney, liver, heart, spleen, stomach and
thymus tissues were harvested at postnatal day 21. A
minimum of six affected animals and 10 unaffected ani-
mals were analyzed at each dosage. Control animals for
these studies included EKI treated and untreated (vehi-
cle only) phenotypically normal littermates. The vehicle
used for intraperitoneal injections was 2% Tween 80,
0.5% methylcellulose in water.
Combination of EKB-569 and WTACE2
Previous studies demonstrated that maximum cyst re-
duction, in the absence of any toxicity, was achieved by
WTACE2 administered at 100 mg/kg, intraperitoneally,
daily [22]. WTACE2 was administered intraperitoneally
at this dose from postnatal day 8 to postnatal day 20, on
days between EKB-569 treatments (nine total doses).
Histology, immunohistology, and determination of
segmental nephron cyst localization
All kidney and liver tissues were fixed in 4.0% para-
formaldehyde in phosphate buffer (pH 7.4) for 30 min-
utes at 4C. Tissues were then washed, dehydrated through
graded acetone, and embedded in ImmunobedTM plastic
embedding medium (Polysciences, Warrington, PA, USA).
Sections were cut at 4 m on an ultramicrotome, mounted
on glass slides, and stained with hematoxylin (all tissues)
or segment-specific lectins (kidney only). Segmental neph-
ron cystic localization and collecting tubule cystic index
were quantitated in each experimental group by combin-
ing morphometric analysis with light microscopy and
immunohistologic techniques [17–20, 27]. Cyst localiza-
tion was studied by segment-specific lectin binding using
Dolichos biflorus agglutinin (DBA) as a marker for col-
lecting tubules and Lotus tetragonolobus (LTA) as a
marker for proximal tubules [13, 17–20, 28]. In liver
tissue, BDE was assessed morphologically by previously
published methods [20].
The immunostaining procedure used was our pre-
viously described postembedded staining technique spe-
cifically developed for localization of antigens and lectins
in plastic sections [29]. Sections 4 m thick were etched,
trypsinized and incubated overnight at 4C with biotinyl-
ated lectins (3.57 ug/mL for LTA and 6.25 ug/mL for
DBA), followed by incubation with extraviden peroxi-
dase (1/400), or extraviden alkaline phosphatase (1/200),
for 90 minutes at room temperature. Sections incubated
with extraviden peroxidase were developed with 0.05%
diaminobenzidine, 0.01% hydrogen peroxide for 10 min-
utes, and those stained with extraviden alkaline phospha-
tase were developed with Fast-Red. All sections were
counterstained with hematoxylin.
Kidney weight to body weight ratio and renal cystic index
At postnatal day 21, total body weights of control
and cystic, treated and untreated, animals were obtained
along with the combined weight of both excised kidneys
for the determination of kidney weight to body weight
ratios. The degree of collecting tubule cyst formation or
cystic index was quantitated by segment-specific mor-
phometric analysis of cyst formation. The index was de-
rived from basic light microscopic morphometric meth-
ods [27] and has been standardized to quantitate cyst
formation in vivo and in vitro [13, 17, 18, 20, 22]. Follow-
ing routine histologic preparation, 10 to12 evenly spaced,
4 m thick sections of kidney were graded for cyst local-
ization and severity of formation in collecting tubule
tubular segments (DBA-positive) [20, 22]. For each
treatment group, a collecting tubule cystic index was
determined on a total of at least six affected pups.
Analysis of renal function and maximal urinary
concentrating ability
Animals were deprived of water for 12 hours prior to
collection of urine samples for urine osmolarity measure-
ments. Blood samples were obtained by cardiac puncture
for serum blood urea nitrogen (BUN) and creatinine
measurements. Serum BUN was quantitatively deter-
mined on an automated clinical chemistry analyzer using
the Boehringer Mannheim urease-triggered methodol-
ogy based upon the method of Talke and Schubert [30].
Serum creatinine was quantitative determined on an au-
tomated clinical chemistry analyzer by the Seelig modi-
fication of the Jaffe method [31].
Hepatic BDE
Following routine histologic preparation, eight evenly
spaced, at least 32 m apart, 4 m thick, hematoxylin-
stained liver sections were graded (0 to 4) for BDE and
biliary epithelial proliferation using previously published
methods [20].
Ultrasonography
Renal ultrasound was performed using a 15 mHz linear
array transducer. Control and cystic animals, ages post-
natal day 7, postnatal day 14, and postnatal day 21, under
normal conditions as well as pharmacologic regimens,
were sedated and length and width of both right and left
kidneys were measured. The accuracy of renal ultra-
sound was evaluated by comparing in vivo ultrasound
measurements to postmortem measurements of excised
kidneys from animals sacrificed immediately following
in vivo renal ultrasound.
Statistical analysis
The significance of differences between experimental
groups was determined by a one-way or two-way analysis
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Fig. 1. Day 21 untreated cystic kidney. Collecting tubules (CT) labeled
with lectin Dolichos biflorus agglutin (DBA). Photograph demonstrates
very large collecting tubule cysts with little normal renal parenchyma,
a typical characteristic of end-stage BPK cystic kidney (original magni-
fication 100).
of variance (ANOVA) with least significant difference
comparisons of the means or Student t test as appro-
priate. [32]. Results are expressed as mean  SD.
RESULTS
Dose response studies
Both normal and cystic mice animals were adminis-
tered EKB, by intraperitoneal injections, at 30, 60 or 90
mg/kg, every 3 days starting at postnatal day 7. Kidney
and liver tissues were harvested at postnatal day 21 and
the following were assessed: kidney weight to body weight
ratios, segment-specific morphometric analysis of a cystic
index, serum BUN, creatinine, and maximum urinary
concentrating ability. Figure 1 demonstrates the large
collecting tubule cystic lesions (cystic index 5) present
in day 21 untreated cystic kidneys. All parameters im-
proved in a dose dependent manner up to the maximum
effective dose of 90 mg/kg, the same dose utilized in our
previously published benchmark treatment protocol with
EKI [20]. Figure 2 demonstrates that maximal reduction
in collecting tubule cyst growth, without morphologic
evidence of renal toxicity, required EKB administration
at 90 mg/kg every 3 days. Table 1 demonstrates that
compared to untreated controls (N  10), animals
treated with EKB (90 mg/kg) (N  6) showed a 70% 
10% (P  0.02) reduction in kidney weight to body
weight ratio, a cystic index reduction of 65%  10%
(P0.02), and a significant reduction in BUN from 1912
to 28  3 (P  0.02). EKB treatment (90 mg/kg every
3 days) also resulted in a 300% reduction in creatinine
and a 275% improvement in maximum urine osmolarity.
These results are similar to those achieved with our pre-
Fig. 2. Representative morphology of (A ) EKB-569–treated kidney
from postnatal day 21 BPK cystic animal and (B) EKI-785–treated kidney
from postnatal day 21 BPK cystic animal. Lotus tetragonolobus (LTA)-
labeled proximal tubule (PT), and Dolichos biflorus agglutin (DBA)-
labeled collecting tubules as shown. Data demonstrate that EKB-569
treatment at 90 mg/kg every 3 days results in dramatic reduction in size
and number of collecting tubule (CT) cystic lesions equivalent to the
reduction of collecting tubule cyst growth with EKI-785 treatment [20]
(original magnification 40).
viously published benchmark treatment trial with EKI
(90 mg/kg every 3 days) (Fig. 2) (Table 1) [20].
Treatment of unaffected mice with EKB from post-
natal day 7 to postnatal day 21 (90 mg/kg every 3 days)
resulted in a 7% decrease in total body weight and a
5% decrease in kidney weight (data not shown). The
kidney weight to body weight ratio of unaffected animals
remained unchanged at 1.2%. However, treatment of
cystic animals with EKB resulted in a markedly reduced
kidney weight to body weight ratio from 22% in un-
treated cystic mice to 6.6% in EKB-treated cystic mice
(body weight reduced 5%, kidney weight reduced 70%).
This reduction in kidney weight to body weight ratio of
cystic EKB-treated animals demonstrates that the re-
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Table 1. Kidney weight/body weight ratios, cystic index and renal function with EKI-785 or EKB-569 treatment
Kidney weight/body weight Collecting tubule BUN mg/dL Maximum urine
% cystic index (CI) CR mg/dL osmolarity
Untreated cystic (N  10) 22.13 4.80.4 1912 36174
0.60.2
Cystic-treated EKI-785 (90 mg/kg) (N  14) 5.63a 1.60.5a 194b 109947b
0.20.1a
Cystic-treated EKB-569 (90 mg/kg) (N  6) 6.62c 1.70.5c 283c 99454c
0.20.1c
Abbreviations are: BUN, blood urea nitrogen; CR, creatinine.
a EKI-785 vs. untreated P  0.02
b EKI-785 vs. untreated P  0.01
c EKB-569 vs. untreated P  0.02
EKB-569 vs. EKI-785, NS
duced kidney size observed was not due to nonspecific,
global effects on growth.
EKB and EKI treatment also altered the cyst localiza-
tion profile of BPK mice. In BPK cystic mice [13], other
murine models of ARPKD (cpk [33], orpk [34]), as well
as human ARPKD [35], cystic lesions first appear in the
proximal tubules. As the disease progresses, the site of
cystic lesions shifts to the collecting tubule. Untreated
BPK mice have an equal ratio of proximal tubule to
collecting tubule cysts at day 10. The majority of cysts
(85% to 90%) in affected mice at postnatal day 21 are
localized to the collecting tubule (from inner medulla
to cortex) and are much larger than those localized to
proximal tubule segments. In EKB- and EKI-treated
BPK postnatal day 21 cystic mice, the ratio of proximal
tubule to collecting tubule cysts is nearly equal and the
proximal tubule cysts are slightly larger than the collect-
ing tubule cysts (Fig. 2).
Combination therapy (EKB-569 and WTACE2)
Normal and cystic mice received EKB, intraperitone-
ally, in doses ranging from 30 mg/kg to 60 mg/kg, every
3 days starting at postnatal day 7. WTACE2 was adminis-
tered intraperitoneally on intervening days at 100 mg/kg.
Figure 3A demonstrates that reduction of EKB to 30
mg/kg in combination with WTACE2 (100 mg/kg) pro-
vided maximum reduction in collecting tubule cyst for-
mation, comparable to the morphologic improvement
with EKB (90 mg/kg every 3 days) (Fig. 3B). As seen
in Table 2, all parameters of cystic disease measured in
this study showed comparable improvement with EKB
alone (90 mg/kg every 3 days) or with the combination
of EKB (30 mg/kg every 3 days) and WTACE2 (100 mg/
kg) when compared to untreated cystic animals.
Figure 4 demonstrates that combination therapy re-
sulted in reduction of BDE comparable to results pre-
viously achieved with EKI [20]. Treatment with 30 mg/kg
EKB and 100 mg/kg WTACE resulted in a significantly
(P  0.02) decreased BDE index value of 1.4 (Fig. 4C)
(Table 2) compared to the untreated control BDE index
value of 3.2 (Fig. 4B) (Table 2).
Fig. 3. Morphologic comparison of (A) EKB in combination with
WTACE2 and (B) EKB alone, in postnatal day 21 BPK kidneys. Shown
are Lotus tetragonolobus (LTA)-labeled proximal tubules (PT) and
Dolichos biflorus agglutin (DBA)-labeled collecting tubules (CT). Data
demonstrate that EKB-569 treatment (30 mg/kg every 3 days) in combi-
nation with WTACE2 (100 mg/kg on intervening days) results in dra-
matic reduction in size and number of collecting tubule cystic lesions
equivalent to the reduction of collecting tubule cyst growth with EKB-
569 (90 mg/kg every 3 days) alone. The dose of EKB-569 can be reduced
by 67% when used in combination with WTACE2 (original magnifica-
tion 40).
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Fig. 4. Representative morphology of postnatal day 21 untreated liver
from cystic bpk/bpk animal (A ), postnatal day 21 normal liver from
unaffected bpk/ animal (B ), and postnatal day 21 EKI-785–treated
liver from cystic bpk/bpk animal (C ). Data demonstrate that (1 ) livers
of cystic animals show extensive BDE (A) [compared to livers of unaf-
fected animals (B)]; and (2 ) EKB treatment results in dramatic reduc-
tion of biliary ectasia (C) vs. untreated liver (A), without morphologic
evidence of liver toxicity [original magnification (A) 20, (B and C) 40].
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Table 3. Accuracy of ultrasound measurements vs. postmortem (length  10	3 cm)
Postnatal day Postnatal day Postnatal day Postnatal day Postnatal day Postnatal day
7 (normal) 7 (cystic) 14 (normal) 14 (cystic) 21 (normal) 21 (cystic)
US 40310 63630 65730 98240 78830 166030
CV % 2.48 4.72 4.60 4.10 3.81 1.81
PM 40010 65030 67020 102225 78430 184050
CV % 2.50 4.62 2.99 2.45 3.83 2.72
Accuracy % 99 98 98 96 99 94
Abbreviations are: US, ultrasound; CV, coefficient of variance; PM, postmortem measurement; accuracy, the correlation between US and PM measurements.
Toxicology
Figure 2A (EKB-treated kidney, postnatal day 21) and
2B (EKI-treated kidney, postnatal day 21) demonstrate
no morphologic evidence of renal toxicity. The lack of
renal toxicity at 90 mg/kg every 3 days is supported by
the fact that serum BUN and creatinine levels as well
as the maximum urinary concentrating ability of treated
postnatal day 21 animals was not significantly different
from untreated control values. Pilot toxicology studies on
other organs demonstrated no compound-related deaths
and no microscopic changes in heart, spleen, stomach,
or thymus with 90 mg/kg or less of EKB administered
intraperitoneally every 3 days.
When used in combination with WTACE 2, EKB at
doses of 50 or 60 mg/kg caused an increased runting of
the animals (12% or greater) without significant im-
provement in renal morphology, BDE, or renal function,
when compared to the 30 mg/kg dose. Additionally, the
combination of EKB at 60 mg/kg with WTACE2 at 100
mg/kg produced a 15% mortality rate when WTACE2
was administered daily between EKB administration.
Eliminating the WTACE2 treatment on day 8 only pre-
vented this mortality but still resulted in increased runt-
ing of both normal and cystic animals.
Renal ultrasound
As seen in Table 3 and Figure 5, renal ultrasound was
effective in identifying cystic animals as early as postnatal
day 7. Both width and length measurements of either
right or left cystic kidneys correlated directly with mor-
phologic assessment of disease progression with and
without treatment (histology, kidney weight to body
weight ratio, and cystic index). Table 3 compares in vivo
ultrasound measurements to postmortem measurements
of excised kidneys taken immediately after the renal
ultrasound. As shown in Table 3, the accuracy of in vivo
renal ultrasound lengths was 98% to 99% accurate for
normal kidneys from postnatal day 7 to postnatal day
21. The accuracy of renal ultrasound for length declined
from 99% at postnatal day 7 to 94% at postnatal day 21
when clearly identifying the margins of such large kid-
neys was more difficult by renal ultrasound.
Fig. 5. Renal ultrasound measurements of (A ) width and (B ) length
of kidney during natural disease progression and with combination
treatment with EKB and WTACE2. Data demonstrate that renal ultra-
sound provides a noninvasive method of monitoring natural disease
course and effectiveness of therapy. Combination treatment of non-
affected animals produced data that were identical to that of normal
untreated control.
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DISCUSSION
Numerous studies demonstrate that EGFR and its li-
gands such as TGF- mediate disease progression in
human and murine PKD (reviewed in [8]). Such studies
demonstrate that (1) EGF and TGF- are cystogenic in
a variety of in vitro systems [15, 17, 26]; (2) cyst fluid
from ADPKD, ARPKD, and rat and murine models
of PKD contain immunoreactive EGF-like peptides in
mitogenic quantities [11, 12]; (3) cystic kidneys have
increased TGF- mRNA levels [36]; (4) overexpression
of TGF- in transgenic mice causes renal cystic abnor-
malities [10]; (5) EGFR is overexpressed and mislocal-
ized to the apical membrane of cystic epithelia in human
ADPKD, human ARPKD, and murine models of ARPKD
and ADPKD [9, 16, 19, 37, 38]; (6) abnormally expressed
apical EGFR in PKD are capable of high-affinity EGF
binding, autophosphorylation, and can initiate a signal-
ing cascade that results in increased mitotic activity [19];
and (7) EGFR tyrosine kinase inhibitors decrease EGF-
driven cyst progression in vitro [17, 26].
In previous studies, we have demonstrated the thera-
peutic effectiveness, in vivo, of EKI, an EGFR tyrosine
kinase inhibitor, and WTACE2, an inhibitor of TGF-
processing in reducing progression of cystic disease in
the BPK murine model of ARPKD [20, 22]. The different
targets of these agents in the EGFR/TGF- axis sug-
gested the possibility that combination therapy might
improve efficacy and/or decrease potential toxicity.
EKI has recently been replaced by a second-genera-
tion compound (EKB) that has improved pharmacoki-
netics and enteral bioavailability, compared to the parent
compound [23].
The effectiveness of EKB was evaluated alone or in
combination with WTACE2 in the BPK murine model
of ARPKD. Specific outcomes evaluated included reduc-
tion of collecting tubule cyst formation and growth, BDE,
and improvement in renal function. EKI is a second-
generation member of a class of synthetic compounds
designed to inhibit EGFR activity by covalently binding
to the ATP binding site of EGFR [21, 23]. EKB inhibits
(1) the catalytic activity of the purified EGFR kinase
(IC50  420 pmol/L), (2) autophosphorylation of EGFR
(IC50  5 nmol/L), and (3) mitogenesis in a variety of
cells which overexpress EGFR [23].
In this study, normal and cystic BPK mice were admin-
istered EKB (30 to 90 mg/kg) by intraperitoneal injection
every 3 days starting at day 7. Kidneys were harvested
at day 21 and the following were assessed: kidney weight
to body weight ratios, segment-specific morphometric
assessment of cyst formation, serum BUN, creatinine,
maximum urine osmolarity, and BDE. All parameters
improved in a dose-dependent manner up to the maxi-
mum effective dose of 90 mg/kg. Compared to untreated
controls (N  10), treatment with EKB alone resulted
in a 70% decrease in kidney weight to body weight ratio
(P  0.02), a 65% reduction in collecting tubule cystic
index (P  0.02), an 85% reduction in serum BUN (P
0.02), 300% reduction in creatinine, a 275% improve-
ment in maximum urinary concentrating ability, and a
64% decrease in BDE.
Comparable improvements in all measures of cystic
disease were achieved with a 67% reduction in EKB dosage
when administered in combination with WTACE2. This
study did not investigate lower doses of WTACE2 in
combination with EKB-569 since previous dose response
studies with WTACE2 [22] demonstrated that maximal
effective dosage was 100 mg/kg daily in this model and
that increasing WTACE2 doses to 250 mg/kg daily pro-
duced no toxicity.
The potential role of the EGFR axis in vascular and
tubulointerstitial injury associated with renal and hepatic
manifestations of PKD is a largely understudied area of
great potential import. Evidence suggests that increased
EGFR activity directly leads to growth of vascular
smooth muscle cells [44], increased fibroblast-specific
protein-1 (FSP-1) expression and increased extracellular
matrix production [45]. All of these phenomena are asso-
ciated with progressive fibrotic injury in PKD and other
chronic progressive nephropathies [46]. Therefore, the
inhibition of EGFR activity may provide dual therapeu-
tic benefits by limiting tubular epithelial proliferation
while reducing vascular and interstitial changes.
Additional studies are required to determine the pre-
cise window during which EGFR inhibition can be uti-
lized safely to reduce cyst development and progressive
enlargement, as well as the consequences of long-term
therapy targeting the EGFR axis. The vital role of the
EGFR axis in normal organogenesis seemingly precludes
the use of this therapy during gestation or the early
postpartum period. The use of EKB in combination with
WTACE2 will hopefully provide the opportunity to maxi-
mize the efficacy to toxicity ratio by ultimately decreasing
the amount of EKB required for chronic therapy in PKD.
The results of this study do not address the specific
mechanisms by which a mutated murine or human
ARPKD gene leads to qualitative and quantitative ab-
normalities in EGFR expression. The mutated genes
responsible for murine models of PKD (CPK, BPK, and
ORPK models) are on different chromosomes and none
of these genes are syntenic with the human ARPKD or
ADPKD genes. Increased apical collecting tubule EGFR
expression demonstrated in both murine and human
ARPKD and ADPKD is thus a common cellular pheno-
type downstream from a number of different primary
gene defects in PKD [9, 13, 16, 18, 19, 34, 38]. A number
of studies have demonstrated that this common cellular
phenotype is maintained in primary and conditionally
immortalized cystic epithelial in vitro [9, 19, 39]. This,
along with the identification of PKD1, PKD2, and most
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recently PKHD1, provide the opportunity to investigate
the interactions between primary PKD mutations, EGFR
mislocalization, and elucidation of pathogenic signaling
pathways due to aberrant signaling from apical EGFR
and mutated PKD proteins. Recent evidence demon-
strates that both human and murine PKD proteins local-
ize to primary cilia on the apical surface of all renal
epithelial cells except intercalated cells, suggesting a role
for primary cilia in PKD [40–43]. Although this hypothe-
sis has yet to be proven, future discoveries regarding PKD
protein interactions, and the normal and abnormal sig-
naling pathways of PKD proteins may identify potential
therapeutic targets downstream of the EGFR. However,
inhibition of EGFR activity has proven to be the most
effective in vivo treatment in murine PKD to date [47, 48].
We speculate that targeting the cystic EGFR cellular
phenotype common to murine and human ARPKD and
ADPKD with compounds such as EKB, in combination
with inhibitors of ligand availability, such as WTACE 2,
may have therapeutic value in the treatment of human
PKD.
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